Your session is about to expire
← Back to Search
Antioxidant
Lipoic Acid for Atherosclerosis
Phase 2 & 3
Waitlist Available
Led By Gerd Bobe, PhD
Research Sponsored by Oregon State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 and 24 weeks
Awards & highlights
Study Summary
This trial will test whether R-alpha lipoic acid supplements can help reduce obesity risk factors.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 and 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 and 24 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Triglycerides
Secondary outcome measures
Body weight and composition
Markers of inflammation and oxidative stress
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Lipoic AcidActive Control1 Intervention
600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
Group II: PlaceboPlacebo Group1 Intervention
Placebo two caps every morning on empty stomach
Find a Location
Who is running the clinical trial?
Oregon Health and Science UniversityOTHER
979 Previous Clinical Trials
7,386,361 Total Patients Enrolled
1 Trials studying Atherosclerosis
50 Patients Enrolled for Atherosclerosis
National Center for Complementary and Integrative Health (NCCIH)NIH
837 Previous Clinical Trials
669,644 Total Patients Enrolled
5 Trials studying Atherosclerosis
570 Patients Enrolled for Atherosclerosis
Oregon State UniversityLead Sponsor
50 Previous Clinical Trials
8,346 Total Patients Enrolled
1 Trials studying Atherosclerosis
50 Patients Enrolled for Atherosclerosis
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger